RY 169.88 -1.0542% SHOP 144.59 -0.959% TD 77.85 -0.1667% ENB 59.62 -0.5505% BN 78.53 -0.971% TRI 223.92 -0.2495% CNQ 47.03 -0.0213% CP 102.49 -0.5627% CNR 147.77 -0.8787% BMO 131.32 -0.0685% BNS 78.4 0.0255% CSU 4463.7002 0.6222% CM 90.42 0.6344% MFC 44.91 -1.3184% ATD 77.0 -0.7604% NGT 60.01 -0.4149% TRP 68.0 -2.2989% SU 56.965 -0.4282% WCN 260.14 -0.653% L 176.45 0.7135%
Last update at 2024-11-20T19:21:00Z
Top TSX Growth Companies With High Insider Ownership October 2024
Mon 21 Oct 24, 12:03 PMTop TSX Growth Stocks With Insider Ownership October 2024
Fri 18 Oct 24, 12:00 PMOctober 2024's Top TSX Growth Companies With High Insider Ownership
Thu 17 Oct 24, 08:31 PMTSX Growth Companies With High Insider Ownership October 2024
Wed 16 Oct 24, 08:31 PMTop TSX Growth Companies With High Insider Ownership In October 2024
Wed 16 Oct 24, 12:01 PMTSX Growth Stocks With High Insider Ownership Featuring Three Top Picks
Tue 15 Oct 24, 08:31 PMTSX Growth Companies With High Insider Ownership Including 3 Standout Stocks
Mon 14 Oct 24, 08:31 PMHigh Growth TSX Stocks Insiders Are Betting On
Mon 14 Oct 24, 12:04 PM3 TSX Growth Companies With High Insider Ownership Expecting 96% Earnings Growth
Fri 11 Oct 24, 12:07 PMOctober 2024 TSX Growth Companies With Strong Insider Ownership
Thu 10 Oct 24, 08:32 PM| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | -10.04800M | -22.57700M | -17.28900M | -8.27707M | -4.70803M |
| Minority interest | - | - | - | - | - |
| Net income | -10.04800M | -22.64600M | -17.39100M | -8.34834M | -4.70803M |
| Selling general administrative | 6.99M | 7.72M | 6.49M | 2.49M | 2.21M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| Reconciled depreciation | 0.00400M | 0.04M | 0.04M | 0.00789M | 0.00682M |
| Ebit | -16.30300M | -22.30000M | -17.18700M | -8.20580M | -4.70803M |
| Ebitda | -16.29800M | -22.26200M | -17.14700M | -8.19791M | -4.70121M |
| Depreciation and amortization | - | 0.04M | 0.04M | 0.00789M | 0.00682M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -16.30300M | -22.30000M | -17.18700M | -8.20580M | -4.72728M |
| Other operating expenses | - | 22.47M | 17.39M | 8.24M | 4.73M |
| Interest expense | - | 0.07M | 0.00000M | 0.00000M | 0.02M |
| Tax provision | - | - | - | - | - |
| Interest income | 6.25M | 0.07M | 0.11M | 0.03M | 0.00010M |
| Net interest income | 0.91M | 0.07M | 0.31M | 0.00673M | 0.00010M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | 0.07M | 0.10M | 0.07M | - |
| Total revenue | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total operating expenses | 16.30M | 22.47M | 17.39M | 8.24M | 4.73M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 5.34M | -0.27700M | -0.10200M | -0.07127M | 0.02M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -10.04800M | -22.57700M | -17.28900M | -8.27707M | -4.70803M |
| Net income applicable to common shares | -10.04800M | -22.57700M | -17.28900M | -8.27707M | -4.70803M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 |
| Total assets | 19.13M | 36.45M | 23.46M | 42.25M | 38.00M |
| Intangible assets | 0.06M | 0.06M | 0.07M | 0.07M | 0.08M |
| Earning assets | - | - | - | - | - |
| Other current assets | 0.93M | - | 1.55M | - | - |
| Total liab | 13.94M | 6.96M | 2.62M | 4.11M | 1.85M |
| Total stockholder equity | 5.19M | 29.49M | 20.84M | 38.15M | 36.15M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.79M | 3.16M | 0.95M | 1.83M | 1.32M |
| Common stock | 100.92M | 100.92M | 83.67M | 79.59M | 56.58M |
| Capital stock | 100.92M | 100.92M | 83.67M | 79.59M | 56.58M |
| Retained earnings | -106.44700M | -80.98100M | -70.93300M | -48.35600M | -31.06672M |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | - | - | - | - |
| Cash | 16.98M | 33.60M | 20.54M | 30.38M | 22.70M |
| Cash and equivalents | - | 33.60M | 20.54M | 30.38M | 22.70M |
| Total current liabilities | 2.86M | 6.96M | 2.62M | 4.11M | 1.82M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -16.98200M | - | -20.53500M | -30.34100M | -22.63034M |
| Short term debt | - | 0.00000M | 0.00000M | 0.03M | 0.04M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | - | - | 0.03M | 0.07M |
| Other stockholder equity | 10.70M | 0.06M | 7.93M | 6.68M | 10.39M |
| Property plant equipment | - | - | 0.00000M | 0.03M | 0.07M |
| Total current assets | 19.08M | 36.38M | 23.39M | 42.15M | 37.85M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 29.43M | 20.77M | 38.07M | 36.07M |
| Short term investments | - | - | 0.00000M | 10.01M | 15.00M |
| Net receivables | 1.16M | 0.85M | 1.31M | 0.41M | 0.06M |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 2.07M | 1.62M | 1.67M | 2.25M | 0.46M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.02M | - | 0.17M | 0.23M | 0.25M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | 56.58M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -0.00000M | - | - | - | 0.14M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.06M | 0.06M | 0.07M | 0.10M | 0.14M |
| Capital lease obligations | - | - | 0.00000M | 0.03M | 0.07M |
| Long term debt total | - | 0.00000M | 0.00000M | 0.00000M | 0.03M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | 0.00000M | 10.05M | 5.01M | -15.00000M | -0.35446M |
| Change to liabilities | 1.18M | -1.45200M | 2.29M | -0.93156M | 0.63M |
| Total cashflows from investing activities | 0.00000M | 10.05M | 5.01M | -15.00000M | -0.35446M |
| Net borrowings | - | -0.03700M | -0.03900M | -0.00339M | -0.00339M |
| Total cash from financing activities | 24.76M | 3.88M | 18.26M | 44.28M | 6.82M |
| Change to operating activities | - | - | - | - | - |
| Net income | -10.04800M | -22.57700M | -17.28900M | -8.27707M | -4.70803M |
| Change in cash | 13.06M | -9.84000M | 7.68M | 20.33M | -1.56776M |
| Begin period cash flow | 20.54M | 30.38M | 22.70M | 2.37M | 3.94M |
| End period cash flow | 33.60M | 20.54M | 30.38M | 22.70M | 2.37M |
| Total cash from operating activities | -12.65700M | -23.58400M | -15.31100M | -8.95440M | -8.03701M |
| Issuance of capital stock | 24.76M | 3.51M | 11.41M | 38.38M | 3.58M |
| Depreciation | 0.00400M | 0.04M | 0.04M | 0.00789M | 0.00682M |
| Other cashflows from investing activities | 0.00000M | 10.05M | 5.01M | -15.00000M | -0.35446M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 1.23M | -0.39200M | -1.61200M | 0.14M | 0.06M |
| Sale purchase of stock | 24.76M | 3.92M | 18.30M | 40.75M | 3.58M |
| Other cashflows from financing activities | - | 0.41M | 6.88M | 5.91M | 3.24M |
| Change to netincome | -5.02300M | 0.80M | 1.26M | 0.11M | -4.01945M |
| Capital expenditures | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 2.41M | -1.84400M | 0.68M | -0.79264M | 0.68M |
| Stock based compensation | 1.37M | 1.42M | 1.01M | 1.12M | 1.00M |
| Other non cash items | -0.97500M | -0.61600M | 0.25M | -1.01756M | -5.01807M |
| Free cash flow | -12.65700M | -23.58400M | -15.31100M | -8.95440M | -8.03701M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (CAD) | Price (CAD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to EBITDA (x) | |
|---|---|---|---|---|---|---|---|---|
| MDNA Medicenna Therapeutics Corp |
-0.12 7.41% | 1.50 | - | 204.08 | - | 6.92 | -6.1093 | |
| FRX Fennec Pharmaceuticals Inc |
0.70 12.30% | 6.39 | 58.90 | 212.77 | 3.27 | 57.98 | 2.14 | 15.89 |
| EPRX Eupraxia Pharmaceuticals Inc |
0.61 13.26% | 5.21 | - | - | - | 7.62 | -3.8823 | |
| ONC Oncolytics Biotech Inc |
-0.08 5.41% | 1.40 | - | - | - | 6.21 | -2.4457 | |
| TH Theratechnologies Inc. |
0.02 1.19% | 1.70 | - | 18.32 | 0.97 | 19.46 | 0.93 | 6.74 |
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
2 Bloor Street West, Toronto, ON, Canada, M4W 3E2
| Name | Title | Year Born |
|---|---|---|
| Dr. Fahar Merchant Ph.D. | Founder, Chairman, Pres & CEO | 1957 |
| Ms. Rosemina Merchant B.Sc., M.E.Sc | Founder, Chief Devel. Officer & Director | 1957 |
| Ms. Elizabeth Williams C.A., CPA, CA, CPA | CFO & Corp. Sec. | 1978 |
| Dr. Martin Bexon M.D., MBBS | Acting Chief Medical Officer & Head of Clinical Devel. | NA |
| Dr. Samuel R. Denmeade M.D. | Scientific Advisor | NA |
| Dr. Fahar Merchant Ph.D. | Founder, Chairman, President & CEO | 1957 |
| Ms. Rosemina Merchant B.Sc., M.E.Sc | Founder & Chief Development Officer | 1957 |
| Mr. David Hyman CA, CBV | Chief Financial Officer | 1973 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...